About this trial
Anterior Knee Pain (AKP) is a common condition that can be challenging to treat effectively. The main goal of treatment regimens is to improve the function of the knee. However, treatment can be challenging due to the knee pain experience. Cingal™ contains hyaluronic acid (HA), which acts as a joint lubricant, and the corticosteroid triamcinolone hexacetonide (TH). Some studies have shown that Cingal™ can improve joint function and provide short-term pain relief.
Eligibility criteria
Qualifiers
Age 18 - 35 years
Standard weight-bearing AP and skyline view knee x-rays
Retropatellar or peripatellar knee pain for a minimum of 2 months
Confirmed diagnosis of AKP that has failed to improve with a minimum of 6 weeks of conservative treatment (activity modification, supervised physiotherapy, exercise therapy, taping or bracing, NSAIDS)
Disqualifiers
X-ray evidence of knee osteoarthritis or fracture
Meniscal or ligamentous injury assessed or suspected on clinical examination
Previous knee surgery
History of patellar instability
Trial design
Treatments tested in this trial
- Cingal